1 week Ago By Defense World Staff
AtriCure, Inc. ( NASDAQ:ATRC – Get Free Report ) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,600,000 shares, a drop of 5.
3% from the November 30th total of 1,690,000 shares. Based on an average trading volume of 508,100 shares, the short-interest ratio is presently 3.1 days.
AtriCure Price Performance ATRC stock opened at $30.56 on Thursday. The company has a market capitalization of $1.
49 billion, a P/E ratio of -36.82 and a beta of 1.40.
The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.
62. AtriCure has a 52-week low of $18.94 and a 52-week high of $39.
04. The business has a 50-day simple moving average of $33.60 and a two-hundred day simple moving average of $27.
99. AtriCure ( NASDAQ:ATRC – Get Free Report ) last posted its earnings results on Tuesday, October 29th. The medical device company reported ($0.
17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02.
AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%.
The firm had revenue of $115.91 million for the quarter, compared to analysts’ expectations of $112.23 million.
During the same quarter last year, the firm earned ($0.20) EPS. The company’s quarterly revenue was up 17.
9% compared to the same quarter last year. Research analysts expect that AtriCure will post -0.72 EPS for the current fiscal year.
Hedge Funds Weigh In On AtriCure Wall Street Analyst Weigh In ATRC has been the subject of several research reports. Oppenheimer raised their target price on AtriCure from $32.00 to $36.
00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $40.
00 target price on shares of AtriCure in a research note on Tuesday, December 17th. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $61.
00 and gave the company a “buy” rating in a research note on Monday, December 9th. UBS Group raised their target price on AtriCure from $35.00 to $40.
00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, StockNews.com upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Saturday, September 14th.
One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and an average price target of $42.00.
Check Out Our Latest Stock Analysis on AtriCure About AtriCure ( Get Free Report ) AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. Recommended Stories Five stocks we like better than AtriCure What does consumer price index measure? Work and Play: Investing in the Rise of Bleisure Travel Expert Stock Trading Psychology Tips Top Dividend Stocks to Buy Now as Bond Yields Could Lower How to Know Which Cryptocurrency to Buy: A Guide for Investors SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.
com's FREE daily email newsletter ..
